Clinical Trial Update: A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II clinical study to evaluate safety, pharmacokinetics, and preliminary efficacy of IMM2510 in combination with chemotherapy as first-line treatment for n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• IMM2510

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: NSCLC, TNBC | Phase 2 | Status: NOT_YET_RECRUITING